Effects of the PI-3 kinase inhibitor LY294002 (LY) have been examined in relation to responses of human leukemia cells to histone deacetylase inhibitors (HDIs). Coexposure of U937 cells for 24 h to marginally toxic concentrations of LY294002 (e.g., 30 lm) and sodium butyrate (SB; 1 mm) resulted in a marked increase in mitochondrial damage (e.g., cytochrome c and Smac/DIABLO release, loss of DW m ), caspase activation, and apoptosis. Similar results were observed in Jurkat, HL-60, and K562 leukemic cells and with other HDIs (e.g., SAHA, MS-275). Exposure of cells to SB/LY was associated with Bcl-2 and Bid cleavage, XIAP and Mcl-1 downregulation, and diminished CD11b expression. While LY blocked SBmediated Akt activation, enforced expression of a constitutively active (myristolated) Akt failed to attenuate SB/LY-mediated lethality. Unexpectedly, treatment of cells with SB7LY resulted in a marked reduction in phosphorylation (activation) of p44/42 mitogen-activated protein (MAP) kinase. Moreover, enforced expression of a constitutively active MEK1 construct partially but significantly attenuated SB/LY-induced apoptosis. Lastly, cotreatment with LY blocked SB-mediated induction of p21 CIP1/WAF1 ; moreover, enforced expression of p21 CIP1/WAF1 significantly reduced SB/LY-mediated apoptosis. Together, these findings indicate that LY promotes SBmediated apoptosis through an AKT-independent process that involves MEK/MAP kinase inactivation and interference with p21 CIP1/WAF1 induction.
Introduction
Histone deacetylase inhibitors (HDIs), including the short-chain fatty acid sodium butyrate (SB) and its closely related derivative phenylbutyrate (PB) (Sowa and Sakai, 2000) , represent a class of agents that modulate chromatin structure by regulating histone acetylation status (Grunstein, 1997) . HDIs regulate the expression of diverse genes, particularly those involved in growth arrest and differentiation (Marks et al., 2001 ). Owing to their ability to arrest growth and to induce apoptosis or differentiation in diverse neoplastic cell types, including human myeloid leukemic cells and colon cancer (Marks et al., 2000) , attention has recently focused on the use of such compounds in cancer therapy. In addition to butyrates, other HDIs, including depsipeptide (Byrd et al., 1999) suberanoyl hydroxamic acid (SAHA) (Vrana et al., 1999) and MS-275 (Lee et al., 2001) , are currently under clinical evaluation (Vigushin and Coombes, 2002) .
The fate of individual cells in response to environmental damage is tightly controlled by the balance between survival and death pathways. Phosphatidyl inositol 3-OH kinase (PI-3K) is one of the major signaling molecules that protect cells from apoptosis in response to a variety of noxious stimuli, including chemotherapeutic drugs (Nakashio et al., 2000; Page et al., 2000) . PI-3 kinase is a heterodimeric lipid kinase consisting of a p85 kDa regulatory subunit and p110 catalytic subunit. Activated PI-3 kinase phosphorylates the 3 0 -OH position of phosphatidyl inositol (PI), PI(4)P, and PI(4,5)P2, generating three signaling phospholipids: PI(3)P, PI(3-4)P2, and PI(3,4,5)P3, respectively. These lipids bind to the pleckstrin homology (PH) of diverse proteins, among which protein kinase B or AKT is one of the most extensively studied. Binding of AKT to the cell membrane via phosphatidyl inositol PI (3, 4)P2 and PI(3, 4, 5)P3 permits its phosphorylation by the PIdependent kinase PDK1 and a putative PDK2 on threonine 308 and serine 473, respectively. Phosphorylation on Thr308 is required for AKT activation, whereas phosphorylation on Ser473 is involved in amplification of this process (Alessi and Cohen, 1998) . The phosphorylation of these two sites, which are critical for AKT activation, is completely inhibited by the selective PI-3 kinase inhibitor, LY 294002 (LY), an analog of the naturally occurring bioflavinoid quercetin (Vlahos et al., 1994) . Akt plays a key role in protecting cells from apoptosis through interactions with diverse downstream targets including NF-kB, Bad, caspase-9, and p53 among others (Testa and Bellacosa, 2001) . Akt also interacts with numerous other cell cycle regulatory proteins, including cyclin D1, p27 KIP1 , FKRH, and the cyclin-dependent kinase inhibitor (CDKI) p21 CIP1/WAF1 (Romashkova and Makarov, 1999) . The latter has been shown to exert antiapoptotic effects that are distinct from cell cycle regulatory actions (Asada et al., 1999) .
The p44/42 mitogen-activated protein kinase (MAP kinase; extracellular-regulated kinase; ERK) represents, along with p38 MAP kinase and c-Jun N-terminal kinase (JNK), one of three parallel serine/threonine kinase modules that regulate diverse cellular processes, including cell proliferation, differentiation, and apoptosis (Fan and Chambers, 2001) . Although exceptions exist, the bulk of evidence suggests that p44/42 promotes cell survival, whereas p38 and JNK facilitate cell death (Xia et al., 1995) . Additionally, the finding that pharmacologic inhibitors of MAP kinase kinase (MEK1/2) block neoplastic cell maturation (Miranda et al., 2002) suggests that MAP kinase also plays a critical role in the differentiation process. In this regard, the observation that MAP kinase lies upstream of p21 CIP1/WAF1 (Balmanno and Cook, 1999) , induction of which is required for differentiation induction (Asada et al., 1998) , may be relevant.
Currently, little information is available concerning the contribution of the PI-3K/Akt pathway to the response of leukemic cells to HDIs. Recently, Wang (Wang et al., 2002) reported that LY294002 potentiated HDI-mediated lethality in the KM20 human colon cancer cell line in association with diminished activation of Akt. However, the functional role of Akt inactivation in this phenomenon remains to be defined. To address this and related issues, we have examined the impact of dysregulation of the PI-3K/Akt pathway on the response of human leukemia cells to HDIs. Our results indicate that LY294002 dramatically enhances HDImediated mitochondrial damage and apoptosis in human leukemia cells, but that these events are more closely related to interference with induction of Raf/ MEK/ERK and p21 CIP1/WAF1 than to inhibition of the Akt pathway.
Results

Cotreatment of U937 cells with PI-3 kinase inhibitor LY and SB results in a striking increase in apoptosis
Initial studies were undertaken to determine whether blocking the PI-3 kinase pathway sensitized human leukemia U937 cells to histone deacetylase inhibitors. A 24-h exposure to 1 mm SB or 30 mm LY minimally increased the percentage of apoptotic cells as determined by Annexin V-FITC staining (Figure 1a) . However, combined exposure to these agents resulted in a striking increase in apoptosis (e.g., to 460% of cells) (Figure 1a) .
A dose-response study in U937 cells revealed that LY, administered at a concentration of 10 mm for 24 h, significantly enhanced apoptosis in cells exposed to 1 mm SB, that this effect was even more marked at 20 mm LY, and that the majority of cells were apoptotic at LY concentrations X25 mm (Figure 1b) . Similarly, an SB dose-response curve in cells exposed to 30 mm LY revealed that SB at concentrations X0.5 mm resulted in a marked induction of apoptosis, and that the large majority of cells were apoptotic following exposure to SB concentrations X1 mm (Figure 1c) . Median dose effect analysis (Chou and Talalay, 1984) of SB/LY interactions over a range of drug concentrations yielded combination index values considerably o1.0 (e.g., o0.3), corresponding to synergistic interactions (data not shown).
Finally, a time course study demonstrated that an increase in apoptosis in cells exposed to 1 mm SB in conjunction with 30 mm LY was first noted at 16 h (30% of cells), and that the majority of cells were apoptotic by 24-48 h (Figure 1d ). Together, these findings indicate that LY294002 strikingly increases HDI-mediated lethality in human leukemia cells in a concentration-and dose-dependent manner. Exposure of U937 cells to a minimally toxic concentration of wortmannin (500 nm), another PI-3 kinase inhibitor, also significantly enhanced SB-induced apoptosis (data not shown).
Potentiation of HDI-related lethality by LY can be extended to other HDIs and other leukemia cell types As shown in Figure 2a , exposure to LY (30 mm) or SB (1 mm) alone for 24-48 h minimally induced apoptosis in human promyelocytic (HL-60), Jurkat lymphoblastic, or Bcr/Abl þ K562 leukemia cells, whereas combined treatment resulted in a marked increase in cell death in each of the leukemia cell lines. In addition, while a 24 h exposure to the HDIs 1 mm SAHA or 1 mm MS-275 was minimally toxic to U937 cells, combination with 30 mm LY, which was essentially nontoxic by itself, resulted in a pronounced increase in lethality (Figure 2b) . Thus, the marked potentiation of apoptosis by SB and LY in U937 cells could be extended to include other human myeloid and lymphoid leukemia cell types as well as other HDIs.
Coadministration of LY blocks SB-mediated differentiation
Treatment of U937 cells with 1 mm SB for 72 h induced expression of the maturation marker CD11b in B40% of cells (Figure 2c ). When LY (15 mm) was coadministered, the increase in CD11b expression was essentially abrogated. This finding indicates that potentiation of SB-mediated apoptosis by LY is accompanied by a reciprocal reduction in leukemic cell maturation.
Cotreatment with LY and SB results in marked mitochondrial damage and caspase activation in U937 cells
Consistent with the preceding results, Western blot analysis showed that coexposure of U937 cells to LY (30 mm) and SB (1 mm) for 24 h resulted in very pronounced cleavage of procaspase-3, caspase-8, and a major downstream caspase substrate, PARP, events classically associated with apoptosis ( Figure 3a) . In contrast, treatment with these agents individually was considerably less effective.
The effects of SB/LY treatment on loss of mitochondrial membrane potential (MMP: Dc m ) as well as release of cytochrome c and Smac/DIABLO into the cytosol were then assessed (Figures 3b and c) . The time course study shown in Figure 3b demonstrates that whereas 1 mm SB or 30 mm LY alone had a marginal effect on Dc m , combined treatment resulted in an increase in the percentage of cells displaying a loss of Dc m at 6 h, a phenomenon that was very pronounced at exposure intervals of 18 h. Furthermore, the latter effect was largely blocked by the pan-caspase inhibitor Boc-D-fmk (Figure 3b ), indicating that loss of Dc m in SB/LYtreated cells lies downstream of caspase cascade activation. In addition, exposure to 1 mm SB or 30 mm LY individually for 24 h failed to induce cytochrome c or Smac/DIABLO release into the cytosol. However, combined treatment resulted in a very substantial increase in cytochrome c redistribution by 18 h (data not shown), and in Smac/DIABLO cytosolic release by 24 h (Figure 3c ). However, in marked contrast to Smac/ DIABLO, the dramatic increase in cytochrome c release in SB/LY-treated cells was not prevented by Boc-Dfmk. Together, these findings indicate that release of cytochrome c from the mitochondria in SB/LY-treated cells proceeds independently of caspase activation, whereas Smac/DIABLO release and loss of Dc m lie downstream of this process. of full-length Bid, Mcl-1, and XIAP proteins were noted by 24 h in cells exposed to both LY and SB, but not in cells exposed to the agents individually. Bcl-2 cleavage was also observed in cells exposed to the combination of LY þ SB for 18 h. In view of evidence that Bcl-2 attenuates mitochondrial damage and protects the cell from agents that act primarily through the intrinsic apoptotic pathway (Gross et al., 1999) , effects of ectopic expression of Bcl-2 were then examined in relation to SB/LY-induced apoptosis. As shown in Figure 4b , U937 cells ectopically expressing Bcl-2 (D9) were largely insensitive to the lethal effects of combined treatment with SB and LY (24 h 
SB triggers AKT cascade activation, an event that is opposed by LY
In view of evidence that AKT plays a critical role in prosurvival properties of PI-3 kinase (Nicholson and Anderson, 2002) , activation of AKT in SB/LY-treated cells was then analysed by Western blot analysis using a phospho-specific Ser473 AKT antibody. As shown by the time course study displayed in Figure 5a , SB (1 mm) alone induced AKT phosphorylation in U937 cells as early as 10 min following treatment, and this effect persisted over the ensuing 2 h. However, a decline to basal levels was noted by 4 h. Significantly, at each time point evaluated, LY largely abrogated SB-induced AKT phosphorylation. AKT activation by SB treatment was confirmed by parallel increases in phosphorylation of GSK-3 and forkhead transcription factor (FKHR), two major AKT downstream targets (Nicholson and Anderson, 2002) (Figure 5b ). In addition, coadministration of LY substantially inhibited SB-induced increases in GSK-3 and FKHR phosphorylation. Thus, coadministration of LY blocked early SB-mediated phosphorylation of AKT in human leukemia cells, and diminished basal levels at later intervals.
Ectopic expression of constitutively activated Akt fails to attenuate SB/LY-mediated apoptosis in human leukemia cells
To determine the functional significance of AKT inactivation in SB/LY-treated cells, Jurkat lymphoblastic leukemia cells that inducibly express a constitutively active myc-tagged myristoylated AKT (myr-AKT) form in response to doxycycline were employed. Exposure of these cells to 2 mg/ml of doxycycline resulted in a marked accumulation of myr-AKT and a pronounced increase in AKT phosphorylation at Ser473 (Figure 6a ). Notably, administration of LY, either alone or in combination with SB for 4 h (or 16 h; data not shown), did not significantly alter myr-AKT expression or levels of phospho-AKT in cells cultured in the presence of doxycycline. However, contrary to expectations, enforced activation of AKT failed to protect cells from apoptosis induced by SB alone or by the SB/LY combination (P40.05 in each case) (Figure 6b ). Similar results were obtained when eight separate clones that inducibly expressed myr-AKT were employed (data not shown). Together, these results argue against a major functional role for AKT inactivation in the marked potentiation of SB-induced apoptosis by the PI-3K inhibitor LY.
Apoptosis in LY/SB-treated cells is associated with a decrease in MEK/p44/42 and increase of p38 and JNK MAP kinase activity in U937 cells
To examine the role of the MAP kinase signaling pathway in SB/LY-induced apoptosis, we examined the activity of p44/42, JNK, and p38 MAP kinases in U937 Figure 5 SB triggers AKT cascade activation, events that are opposed by LY. U937 cells were exposed to 1 mm SB 730 mm LY for indicated periods, after which protein lysates were prepared and subjected to Western blot using phospho-Ser473 AKT antibody (a), phospho-Ser21/9 GSK-3a/b and phospho-Ser256 FKHR specific antibodies (b). Each lane contained 25 mg of protein; two additional studies yielded equivalent results
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cells by Western blot analysis using antibodies specific for the activated form of these kinases. Interestingly, both SB and LY, administered individually as well as in combination, resulted in a marked decline in phosphorylation of p44/42 MAPK as well as its upstream kinase, MEK1, after 4 h of drug treatment (Figure 7) . After 18 h, the phosphorylated forms of p44/42 MAPK and MEK1 were virtually undetectable in drug-treated cells, particularly in those exposed to both LY and SB. As previously reported, p38 phosphorylation increased after individual treatment with 1 mm SB or 30 mm LY at an early interval (e.g., 30 min) (Gratton et al., 2001; Rahmani et al., 2002) while combined treatment resulted in further p38 phosphorylation. However, these effects were not sustained, and reverted to basal levels by 4 h. Lastly, while SB alone did not stimulate JNK activation, a moderate increase in phosphorylation was observed in cells exposed to LY for 18 h, and a more prominent increase was observed in cells exposed to both agents. Thus, combined exposure of leukemia cells to SB and LY was associated with multiple perturbations in MAPK signaling pathways, including an early and very pronounced decline in levels of phosphorylated MEK1/ ERK1-2, early activation of p38, and late activation of JNK.
SB/LY-mediated lethality proceeds through a p38 and JNK MAPK-independent mechanism
To assess the functional significance of early p38 and late JNK MAP kinase activation in LY/SB-induced apoptosis, SB203580 (Young et al., 1997) and SP600125 (Bennett et al., 2001) , pharmacologic inhibitors of p38 and JNK, respectively, were used. As shown in Figure 8 , coadministration of SB203580 as well as SP600125 with the LY/SB regimen failed to modify the extent of apoptosis, reflected by Annexin V staining (Figure 8a ), or the loss of mitochondrial membrane potential, manifested by a decline in DiOC 6 uptake (Figure 8b ; P40.05 in each case). These findings argue against a functional role for p38 and JNK MAP kinases in potentiation of SB-mediated apoptosis by LY.
Downregulation of MEK/MAP kinase plays a functional role in apoptosis induced by the SB/LY regimen
To investigate the functional role of MEK/p44/42 MAPK inactivation in SB/LY-induced apoptosis, a Jurkat line that inducibly expresses a constitutively active human MEK1 construct under doxycycline control was employed. Exposure of these cells to 2 mg/ ml doxycycline induced a marked accumulation of HAtagged constitutively active MEK1, accompanied by a pronounced increase in p44/42 MAPK phosphorylation (Figure 9a ). Significantly, activation of this pathway by doxycycline was readily apparent in cells exposed to LY, SB, or to the combination of LY and SB. Furthermore, in marked contrast to results obtained in cells expressing constitutively active Akt or exposed to SB203580 or SP600125, activation of the MEK/p44/42 MAPK pathway by doxycycline resulted in a partial but significant decline in SB/LY-mediated apoptosis (Po0.01) (Figure 9b ). Equivalent results were obtained in a second Jurkat line that inducibly expresses constitutively active MEK1 (CA17; data not shown). Together, these findings suggest that the marked apoptosis observed in SB/LY-treated leukemia cells depends, at least in part, upon inhibition of the MEK/MAP kinase pathway.
LY blocks SB-mediated induction of p21 CIP1/WAF1 and results in downregulation of p27 KIP1 and cyclin D1 as well as pRb dephosphorylation and cleavage
The effects of SB and LY treatment in U937 cells were then examined in relation to the expression of several cell cycle regulatory proteins ( Figure 10 ). As previously reported (Rahmani et al., 2002) , SB induced p21 CIP1 protein accumulation by 18-24 h. However, this effect was essentially abrogated by LY. Moreover, the caspase inhibitor Boc-D-fmk did not block the downregulation of p21 CIP1 , indicating that this phenomenon did not , that inducibly express myc-tagged myristoylated AKT, were left untreated or treated for 24 h with 2 mg/ml doxycycline, and then exposed to 1 mm SB or 30 mm LY alone or in combination for an additional 4 h. The cells were lysed and subjected to Western blot analysis using anti-c-myc and phospho-Ser473 antibodies. Each lane contained 25 mg of protein; blots were stripped and reprobed with actin or tubulin to ensure equivalent loading and transfer of proteins. Two additional studies yielded equivalent results. (b) AKT CA2 cells were treated as above for 16 and 24 h, after which apoptosis was analyzed using annexin V-FITC assay as described in Materials and methods
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simply reflect caspase-mediated p21 CIP1 degradation (data not shown). Protein levels of p27 KIP1 were substantially reduced following combination treatment, and were accompanied by the appearance of a rapidly migrating species, presumably representing a cleavage fragment. Combined treatment also resulted in a marked reduction in the expression of cyclin D1, but in contrast to p21 CIP1 , cyclin D1 downregulation was antagonized by Boc-D-fmk (data not shown). Finally, consistent with earlier reports (Rahmani et al., 2002) , exposure of U937 cells to SB or LY resulted in an increase in expression of underphosphorylated pRb, accompanied by partial cleavage of the underphosphorylated species (Figure 10 ). However, combined treatment with SB and LY resulted in extensive cleavage of underphosphorylated pRb and a marked diminution in expression of full-length pRb compared to that observed in cells exposed to SB alone. Thus, coadministration of LY disrupted multiple proteins involved in SB-associated G 1 arrest program, particularly induction of the cyclin-dependent kinase inhibitor p21 CIP1/WAF1 .
As p21
CIP1/WAF1 protects leukemic cells from apoptosis induced by diverse agents including HDIs (Asada et al., 1998; Rosato et al., 2001) , an attempt was made to determine whether abrogation of SB-mediated p21 , which was particularly pronounced in SB-treated cells. While LY also attenuated p21 CIP1/WAF1 induction by SB in cells exposed to doxycycline, presumably reflecting interference with upregulation of the endogenous protein, it was unable to abrogate ectopic expression of doxycycline-stimulated p21 CIP1/
WAF1
. Notably, enforced expression of p21 CIP1/WAF1 resulted in a partial but significant reduction in apoptosis compared to cells exposed to SB/LY in the absence of doxycycline (Figure 11b ; Po0.02), supporting the notion that interference with SB-mediated p21 CIP1/WAF1 induction by LY contributes to the lethality of this drug combination.
Discussion
The present studies indicate that interruption of the PI-3 kinase pathway in human leukemic cells markedly increases HDI-mediated mitochondrial damage, caspase activation, and apoptosis. Furthermore, these events are associated with a diminution in HDI-related differentiation. The relation between maturation and apoptosis is complex, and while the differentiation program can itself trigger cell death (Chinetti et al., 1998; Elstner et al., 1998) , under other circumstances these processes are mutually exclusive (Martin et al., 1990) . Moreover, dysregulation of the maturation program, that is, by the cyclin-dependent kinase inhibitor flavopiridol, has been shown to block phorbol ester-and SB-mediated differentiation and to lower the threshold for mitochon- Exposure of U937 cells to SB and LY display a decrease in MEK/p44/42 and increase of p38 and JNK MAP kinase phosphorylation. U937 cells were exposed to 1 mm SB 730 mm LY for indicated times, after which lysates were subjected to Western blot using antibodies recognizing the only phosphorylated (activated) forms of MEK1/2 (Ser217/221), p44/42 (Tyr204), p38 (Tyr182), and JNK (Thr183/Tyr185). Antibodies recognizing the total MEK1 and p44/42 proteins were also used. Each lane contained 25 mg of protein; two additional experiments yielded similar results
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drial damage and apoptosis (Cartee et al., 2001; Rosato et al., 2002) . In this context, PI-3 kinase inhibitors such as LY294002 and wortmannin have been shown to block retinoic acid-and PMA-mediated maturation in HL-60 cells (Lewandowski et al., 2002; Park et al., 2002) , DMSO-and erythropoietin-induced differentiation in erythroleukemia cells (Cataldi et al., 2000; Kubota et al., 2001) , and PDGF and CSF-1 receptormediated maturation in the IL-3-dependent hematopoietic cell line FDC-P1 (Kubota et al., 1998) . The recent observation that administration of LY with SB, an agent known to induce colon cancer cell maturation (Gum et al., 1987) , blocks Akt activation and increases lethality (Wang et al., 2002) is also consistent with this concept. However, it cannot be concluded that disruption of HDI-mediated maturation per se is responsible for the dramatic increase in apoptosis in HDI/ LY-treated cells. An equally plausible explanation is that LY disrupts cytoprotective signaling pathways that prevent HDI-associated lethality, and that the resulting induction of apoptosis precludes engagement of a differentiation program. KIP1 and cyclin D1 as well as pRb dephosphorylation and cleavage. U937 cells were exposed to 1 mm SB 730 mm LY for 24 h after which expression of p21 CIP1/WAF1 , p27 KIP1 , cyclin D1, and underphosphorylated pRb were analysed by Western blot as described in Materials and methods. Each lane contained 25 mg of protein; blots were stripped and reprobed with tubulin to ensure equivalent loading and transfer of proteins. Two additional studies yielded equivalent results
Although the lethal effects of LY have frequently been attributed to Akt inactivation (Nesterov et al., 2001) , the present results suggest that interference with Akt signaling by PI-3 kinase inhibitors plays little, if any, role in promoting HDI-mediated lethality in human leukemia cells. In this regard, there is evidence that inhibition, rather than stimulation, of Akt activity may be involved in hematopoietic cell maturation. For example, Jak3-mediated maturation in 32Dcl3 hematopoietic cells was associated with inactivation of Akt (Rane et al., 2002) , and in Bcr/Abl þ myeloid leukemia cells the tyrosine kinase inhibitor STI571 induced differentiation in association with downregulation of phosphorylated Akt (Fang et al., 2000) . Such findings are difficult to reconcile with the notion that interruption of Akt signaling blocks leukemic cell maturation and reciprocally promotes apoptosis. In fact, the failure of enforced Akt activation to attenuate SB/LY-induced lethality (Figure 6 ) argues against the possibility that Akt downregulation is responsible for potentiation of cell death. In this regard, we have recently reported that enforced expression of constitutively active Akt does significantly protect Jurkat cells from apoptosis induced by combined exposure to LY and the cyclin-dependent kinase inhibitor flavopiridol (Yu et al., 2003) , suggesting that the cytoprotective actions of Akt are highly context-dependent. In the case of LY/HDI-mediated apoptois, an alternative possibility is that LY may disrupt one or more PI-3 kinase-dependent, Aktindependent pathways, that is, CDC42, RAC1, or the serum and glucocorticoid-inducible kinase (SGK), among others (Park et al., 1999; Murga et al., 2002) . For example, the prosurvival effects of glugagon-like peptide-2 (GLP-2) on LY294002-induced cell death in hamster kidney cells has recently been shown to involve PKA-dependent but Akt-independent events (Yusta et al., 2002) . Whether interference with any of these PI-3 kinase-dependent, Akt-independent pathways is responsible for potentiation of HDI-mediated lethality by LY remains to be determined.
In contrast to the apparent lack of involvement of Akt inactivation in LY/SB-mediated lethality, disruption of the MEK/ERK pathway appeared to play a significant functional role in the observed potentiation of cell death. Interestingly, LY and SB individually diminished MEK and ERK phosphorylation, and the combination was particularly effective in this regard. These events were accompanied by the (late) activation of JNK, resulting in a shift away from cytoprotective and toward stress-related, proapoptotic signaling events (Xia et al., 1995) . To the best of our knowledge, LY294002 has not previously been shown to attenuate ERK activation in human leukemia cells, although activation of JNK by PI-3 kinase inhibitors has been observed in hepatocytes (Sidhu et al., 2001) . In addition, LY294002 and wortmannin have been shown to inhibit integrinmediated Raf/MEK/ERK activation (King et al., 1997) , as well as Ras and ERK activation by lysophosphatidic acid (LPA) (Hawes et al., 1996) in Cos 7 cells. Similarly, little information is available concerning downregulation of MEK/ERK by HDIs, although Yu et al. (2002) recently described Raf-1/MEK/ERK downregulation in nonsmall-cell lung cancer (NSCLC) cells exposed to the HDI depsipeptide. The ability of enforced activation of MEK and ERK to attenuate SB/LY-mediated lethality indicates that downregulation of this pathway by the LY/SB regimen plays an important functional role in potentiating mitochondrial damage and apoptosis in leukemic cells. However, the observation that SB and LY, administered individually, were minimally toxic despite inactivating MEK and ERK indicates that the latter events are insufficient, by themselves, to trigger cell death. In this regard, LY/SBmediated downregulation of the antiapoptotic proteins XIAP (Deveraux and Reed, 1999) and Mcl-1 (Moulding et al., 2000) , as well as generation of a putatively proapoptotic Bcl-2 cleavage fragment (Kirsch et al., 1999) , may be relevant.
Several lines of evidence suggest that the ability of LY to block SB-mediated induction of the CDKI p21 CIP1/WAF1 contributed to enhanced lethality of this drug combination. It is known that diverse HDIs, , and that this event plays an important role in G 1 arrest and differentiation induced by such agents, particularly in leukemic cells (Marks et al., 2000) . However, p21 CIP1/WAF1 also antagonizes apoptosis, an action that may stem from binding to and inhibition of caspase-3 (Suzuki et al., 1998) . In the case of HDIs, p21
antisense-expressing cells have been shown to be more susceptible to SB-mediated apoptosis than their wildtype counterparts (Rosato et al., 2001) , and enforced expression of p21 CIP1 is known to protect human colon adenocarcinoma HCT116 cells from the lethal actions of the HDI azelaic bishydroxamic acid (ABHA) (Burgess et al., 2001) . The observation that LY294002 blocked p21 CIP1/WAF1 induction by SB is consistent with the results of an earlier report in which PI-3 kinase inhibition prevented p21 CIP1/WAF1 upregulation in ovarian cancer cells exposed to cisplatin (Mitsuuchi et al., 2000) . Together, such findings support a model in which dysregulation of p21 CIP1/WAF1 by LY lowers the apoptotic threshold of HDI-treated cells, and causes them to engage an alternative, apoptotic program. Consistent with this model, enforced expression of p21
antagonized, albeit partially, the lethality of the LY/ SB regimen. Although the mechanism by which LY prevents p21 CIP1/WAF1 induction is uncertain, this phenomenon has been attributed to GSK-3 activation, and resulting p21 CIP1 proteasomal degradation (Rossig et al., 2002) . However, the inability of ectopic expression of constitutively active Akt to inhibit LY/SB-mediated lethality would argue against this possibility in human leukemia cells. On the other hand, the capacity of LY to downregulate the MEK/MAP kinase axis may be relevant to this issue. For example, a MAP kinase responsive element exists in the p21 CIP1/WAF1 promoter region (Kivinen et al., 1999) , and MEK/MAP kinase inhibitors are known to antagonize p21 CIP1/WAF1 induction (Das et al., 2000) . Thus, the possibility that inactivation of MEK and MAP kinase in LY/SB-treated cells prevents p21 CIP1 induction, and as a consequence, promotes HDI-mediated lethality, appears possible. In any case, the relatively modest protection afforded by enforced p21 CIP1 expression indicates that other factors play critical and potentially more important roles in HDI/LY-related synergism.
In summary, the present studies indicate that interference with PI-3 kinase signaling dramatically increases HDI-mediated mitochondrial injury and apoptosis in malignant hematopoietic cells through an Akt-independent mechanism. On the other hand, the dramatic increase in HDI-related apoptosis observed in LYtreated cells appears to be related to disruption of MEK/MAP kinase and p21 CIP1/WAF1 responses, and possibly perturbations in expression of several other cell cycle-and survival-related proteins. In view of extensive evidence implicating dysregulation of the PI-3 kinase cascade in malignant transformation (Nicholson and Anderson, 2002) , the development of PI-3 kinase inhibitors has been the focus of intense interest (Stein, 2001 ). In addition, a variety of HDIs are currently being evaluated in clinical trials involving patients with hematopoietic and nonhematopoietic malignancies (Vigushin and Coombes, 2002) . Identification of the downstream PI-3 kinase targets, whose interruption is responsible for potentiation of HDI-mediated lethality in neoplastic cells, could provide a rational foundation for the development of novel combination strategies. Accordingly, such studies are currently in progress.
Materials and methods
Cells
U937, HL-60, and Jurkat cell lines were obtained from American Type Culture Collection and were cultured in RPMI 1640 medium (Life Technologies, Inc., Grand Island, NY, USA) supplemented with 10% (v/v) of heat-inactivated fetal calf serum (Hyclone, Logan, UT, USA), and maintained at 371C in a fully humidified atmosphere containing 5 % CO 2 . All experiments were performed on logarithmically growing cells. U937 cells stably overexpressing Bcl-2 protein and their empty vector counterpart (pCEP4) were developed as described previously (Cartee et al., 2001) .
Tet-On-inducible Jurkat cell lines were generated as follows. A constitutively active form of AKT (Myc-tagged myristoylated AKT) and MEK1 (HA-tagged MEK1 S218D/S222D) were obtained from Upstate Biotechnology (Lake Placid, NY, USA). p21 CIP1/WAF1 was a generous gift from Dr P Fisher (Columbia University, NY, USA). Each of these genes was subcloned into the pTRE2-hygro expression vector (Clontech, Palo Alto, CA, USA) by standard techniques and individually transfected into Jurkat 'Tet-On' cells (Clontech) that are stably expressing rtTA (reverse tet transactivator) regulator protein using the electroporation technique. Stable clones from a single cell were selected in the presence of 400 mg/ml of hygromycin and tested for the induced expression of transfected genes. Therefore, stable clones were left untreated or treated for 24 h with 2 mg/ml doxycycline, then harvested, and analysed for myc-AKT, HA-MEK1, and p21 expression by western blot as described below. Phosphorylated AKT (activated) and p44/42 MAPK were also analysed to evaluate the function of transfected AKT and MEK, respectively. For p21 clones, cell cycle arrest and cell growth as well as pRb dephosphorylation were analysed. For each case, several clones were chosen. The clones chosen displayed very low or undetectsble basal expression of transfected genes which are highly induced and functional in response to doxycycline exposure.
Reagents
LY was purchased from Sigma (St Louis, MO, USA). SB and p38 inhibitor SB203580 were obtained from Calbiochem (San Diego, CA, USA). SAHA was purchased from Alexis Corp (San Diego, CA, USA). MS-275 was kindly provided by Dr. O Nakanishi, Shering-Nihon. The broad spectrum cell permeable caspase inhibitor, Boc-D-FMK, was purchased from Enzyme Systems Products (Livermore, CA, USA). All reagents were prepared and used as recommended by their suppliers.
Assessment of apoptosis
Apoptotic cells were identified by two different techniques: Annexin V-FITC staining and morphological assessment of Wright Giemsa-stained cytospin preparations as previously described (Rahmani et al., 2002) .
Protein extraction and Western immunoblotting
Protein extraction and Western blot were performed as previously described in detail (Rahmani et al., 2002) . The primary antibodies used in this study, p21 WAF1/CIP1 , p27 kip1 , and MEK1, were purchased from Transduction Laboratories (Lexington, KY, USA). Underphosphorylated pRb, cytochrome c, caspase-3, cyclin D1, Bax, and Mcl-1 were provided by PharMingen (San Diego, CA, USA). Caspase-8 was purchased from Alexis Corp (San Diego, CA, USA). Bid, cleaved Poly (ADP-ribose) Polymerase (cPARP), phospho-MEK1/2, phospho-AKT, phospho-GSK3a/b, phospho-FKHR, and XIAP were obtained from Cell Signaling Technology (Beverly, MA, USA). Bcl-2 was provided by DAKO (Carpinteria, CA, USA). Phospho-ERK1-2, phospho-JNK, phospho-p38, myc-tag, and HA-tag were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Smac/DIABLO was obtained from Upstate Biotechnology.
Measurement of MMP (Dc m ) and cytochrome c release MMP (Dc m ) was evaluated by using 3,3-dihexylxacarbocyanine iodide (DIOC 6 ) (Molecular Probes; Eugene, OR, USA), a cationic lipophilic fluorochrome. Cells (4 Â 10 4 cells) were incubated for 15 min at 37 o C in 1 ml of 40 nm DIOC 6 , and subsequently analysed by flow cytometry using a Becton Dickinson FACScan. Cytochrome c release into the cytosol was monitored as previously described (Rahmani et al., 2002) .
CD11b expression
CD11b expression was monitored by flow cytometry as previously described (Rahmani et al., 2002) .
Statistical analysis
The significance of differences between experimental conditions was determined using the Student's t-test for unpaired observations.
